Topline data from Cohort B in the Phase 3b VISIBLE study were presented today at the Maui Derm Hawaii 2024 conference.
VISIBLE is the first prospective, large-scale, randomized-controlled trial dedicated to people of color across all skin tones with moderate to severe plaque PsO and scalp PsO to objectively measure clearance and other treatment outcomes with TREMFYA. The VISIBLE clinical program will produce an expansive longitudinal collection of more than 20,000 clinical images across all skin tones to support patients and providers with disease recognition and education. Cohort B of the study enrolled 108 people of color with scalp predominant moderate-to-severe PsO, a clinically proven difficult-to-treat area. TREMFYA demonstrated significant and rapid scalp PsO clearance and improvement in scalp itch as well as patient-reported health-related quality of life (HRQoL) outcomes.
'Scalp psoriasis is highly prevalent and can present unique challenges across diverse populations. In patients of color, cultural factors related to hair care practices and post-inflammatory pigment changes contribute to the burden of scalp psoriasis. These findings from VISIBLE are key to broadening our understanding of scalp psoriasis, and the role TREMFYA can have in treating all patients with this disease,' said
Guselkumab Significant and Rapid Scalp Clearance Data at Week 16 Poster:1
At Week 16, after three doses, patients receiving TREMFYA achieved significantly greater improvements versus placebo: At Week 16, nearly 7 in 10 patients receiving TREMFYA achieved the study's co-primary endpoints, Scalp-Specific Investigator Global Assessment (ss-IGA) score of 0/1 (68.4% vs 11.5% placebo) and Psoriasis Scalp Severity Index (PSSI) 90 response (65.8% vs 3.8% placebo). Of note, 90% of patients who met the study's co-primary endpoints achieved complete scalp clearance (ss-IGA 0 or PSSI 100).
Patients receiving TREMFYA experienced nearly 90 percent improvement from baseline in PSSI (87.6% vs 37.8% placebo) and in Scalp Surface Area (SSA) (86.6% vs 33.4% placebo).
In this previously understudied population, no new safety signals were reported through Week 16.
Guselkumab Patient-Reported Health-Related Quality of Life (HRQoL) Improvements Poster:2
Scalp PsO is often associated with bothersome symptoms such as intense pruritus and scaling. In some cases, it can even result in alopecia which, in most cases, is reversible with appropriate and timely treatment.
At Week 16, nearly 7 in 10 patients receiving TREMFYA (69.4% vs 24% placebo) achieved a clinically meaningful improvement on the Scalp Itch Numeric Rating Scale (NRS).
At Week 16, significantly greater improvements in the Psoriasis Symptoms and Signs Diary (PSSD) and Dermatology Life Quality Index (DLQI) were reported by patients receiving TREMFYA versus placebo across all skin tones.
Guselkumab Patient-Reported Post-Inflammatory Pigmentation Data Poster:3
Post-inflammatory pigment alteration (PIPA) refers to the skin discoloration that may occur after skin inflammation or injury, which is a part of the natural process of inflammatory diseases like psoriasis. PIPA can affect all skin tones and significantly impact quality of life, particularly for those with melanin-enriched skin types.
At baseline, mean score as assessed by the Skin Discoloration Impact Evaluation Questionnaire (SDIEQ) indicated patients were experiencing at least moderate impact of skin discoloration on their HRQoL.
At Week 16, patients treated with TREMFYA reported they have experienced improvements, with only a mild effect from skin discoloration on their HRQOL. TREMFYA is not intended to treat PIPA.
Cohort A of the VISIBLE study, announced in
'Scalp psoriasis can be particularly burdensome to patients as it often impacts more visible areas of the body, including the hairline, forehead, neck, and around the ears, triggering feelings of self-consciousness that limit many people's lifestyle choices,' said
TREMFYA is the first IL-23 inhibitor approved in the
About VISIBLE (NCT05272150)8
VISIBLE (n=211) is a phase 3b, multicenter, randomized, double-blind, placebo-controlled (Weeks 0-16) trial in adult patients (18 years of age) with moderate to severe body and/or scalp psoriasis. Patients were randomized to TREMFYA 100 mg subcutaneous injection at Weeks 0, 4, and 12, then q8w; placebo at Weeks 0, 4, and 12, followed by crossover to TREMFYA at Week 16, Week 20, and q8w. The study was designed to evaluate the efficacy and safety of TREMFYA in skin of color patients (self-identify as non-white) across the entire spectrum of the Fitzpatrick scale (I-VI). The study consisted of 2 cohorts, Cohort A: moderate to severe plaque psoriasis (IGA 3, PASI 12, and body surface area involvement of 10%) and Cohort B: moderate to severe scalp psoriasis (SSA 30%, PSSI 12, ss-IGA 3, and 1 plaque outside the scalp) for at least 6 months before study administration, or central photo review expert confirmed psoriasis diagnosis, or biopsy confirmed psoriasis. The VISIBLE study is still ongoing with an active treatment period from Weeks 16-48 and long-term extension through Week 112 where patients continued receiving TREMFYA q8w.
The study will evaluate approximately 211 participants from the
About TREMFYA (guselkumab)
Developed by Janssen, TREMFYA is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is an important driver of the pathogenesis of inflammatory diseases such as moderate to severe plaque psoriasis (PsO) and active psoriatic arthritis (PsA).4,9 TREMFYA is approved in the
The Janssen Pharmaceutical Companies of
About
At
Cautions Concerning Forward-Looking Statements
This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding development of TREMFYA (guselkumab). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of
Contact:
Email: bharmon1@its.jnj.com
Tel: 267-449-6618
Email: investor-relations@its.jnj.com
(C) 2024 Electronic News Publishing, source